A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups
Primary central nervous system lymphoma (PCNSL) is a highly aggressive and rare extranodal non-Hodgkin lymphoma (NHL). The MSKCC and the IELSG scores represent the most widely used prognostic models, but many changes have occurred in therapeutic protocols since their development. Moreover, many PCNS...
Saved in:
Published in: | Frontiers in oncology Vol. 11; p. 696147 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Switzerland
Frontiers Media S.A
03-08-2021
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | Primary central nervous system lymphoma (PCNSL) is a highly aggressive and rare extranodal non-Hodgkin lymphoma (NHL). The MSKCC and the IELSG scores represent the most widely used prognostic models, but many changes have occurred in therapeutic protocols since their development. Moreover, many PCNSL patients cannot be classified using the IELSG score. We thus aimed to create a novel, effective and feasible prognostic model for PCNSL.
We included 248 PCNSL patients diagnosed with PCNSL. Our primary endpoint was the overall survival (OS) and we used the receiver operating characteristic (ROC) analysis to determine the optimal prognostic cut-off value for LLR (lactate dehydrogenase-to-lymphocyte ratio), neutrophil-to-lymphocyte ratio (NLR) and derived neutrophil-to-lymphocyte ratio (dNLR). Variable associated with OS were evaluated by univariate and multivariate analyses. 124 out of 248 patients were randomly selected as the internal validation cohort.
By univariate analysis, an age >60 years, Eastern Cooperative Oncology Group performance status (ECOG PS) >1, treatment with radiotherapy alone, high-risk groups of Memorial Sloan Kettering Cancer Center (MSKCC) score, NLR >4.74, dNLR >3.29, and LLR >166.8 were significantly associated with a worse OS. By multivariate analysis, the MSKCC score and LLR were confirmed as independent prognostic parameters for poorer OS. OS, however, was not significantly different between low- and intermediate-risk groups according to the MSKCC score, while LLR proved to be prognostically relevant and was thus used to develop a novel, effective three-tier PCNSL scoring system. Of 124 patients, 84 patients with survival data and LLR data were successfully validated by newly established PCNSL LLR scoring system.
In the present study, we demonstrate that a high LLR represents an independent unfavorable prognostic parameter in PCNSL patients which can be integrated into an effective prognostic model. |
---|---|
AbstractList | BACKGROUNDPrimary central nervous system lymphoma (PCNSL) is a highly aggressive and rare extranodal non-Hodgkin lymphoma (NHL). The MSKCC and the IELSG scores represent the most widely used prognostic models, but many changes have occurred in therapeutic protocols since their development. Moreover, many PCNSL patients cannot be classified using the IELSG score. We thus aimed to create a novel, effective and feasible prognostic model for PCNSL. METHODSWe included 248 PCNSL patients diagnosed with PCNSL. Our primary endpoint was the overall survival (OS) and we used the receiver operating characteristic (ROC) analysis to determine the optimal prognostic cut-off value for LLR (lactate dehydrogenase-to-lymphocyte ratio), neutrophil-to-lymphocyte ratio (NLR) and derived neutrophil-to-lymphocyte ratio (dNLR). Variable associated with OS were evaluated by univariate and multivariate analyses. 124 out of 248 patients were randomly selected as the internal validation cohort. RESULTSBy univariate analysis, an age >60 years, Eastern Cooperative Oncology Group performance status (ECOG PS) >1, treatment with radiotherapy alone, high-risk groups of Memorial Sloan Kettering Cancer Center (MSKCC) score, NLR >4.74, dNLR >3.29, and LLR >166.8 were significantly associated with a worse OS. By multivariate analysis, the MSKCC score and LLR were confirmed as independent prognostic parameters for poorer OS. OS, however, was not significantly different between low- and intermediate-risk groups according to the MSKCC score, while LLR proved to be prognostically relevant and was thus used to develop a novel, effective three-tier PCNSL scoring system. Of 124 patients, 84 patients with survival data and LLR data were successfully validated by newly established PCNSL LLR scoring system. CONCLUSIONSIn the present study, we demonstrate that a high LLR represents an independent unfavorable prognostic parameter in PCNSL patients which can be integrated into an effective prognostic model. Primary central nervous system lymphoma (PCNSL) is a highly aggressive and rare extranodal non-Hodgkin lymphoma (NHL). The MSKCC and the IELSG scores represent the most widely used prognostic models, but many changes have occurred in therapeutic protocols since their development. Moreover, many PCNSL patients cannot be classified using the IELSG score. We thus aimed to create a novel, effective and feasible prognostic model for PCNSL. We included 248 PCNSL patients diagnosed with PCNSL. Our primary endpoint was the overall survival (OS) and we used the receiver operating characteristic (ROC) analysis to determine the optimal prognostic cut-off value for LLR (lactate dehydrogenase-to-lymphocyte ratio), neutrophil-to-lymphocyte ratio (NLR) and derived neutrophil-to-lymphocyte ratio (dNLR). Variable associated with OS were evaluated by univariate and multivariate analyses. 124 out of 248 patients were randomly selected as the internal validation cohort. By univariate analysis, an age >60 years, Eastern Cooperative Oncology Group performance status (ECOG PS) >1, treatment with radiotherapy alone, high-risk groups of Memorial Sloan Kettering Cancer Center (MSKCC) score, NLR >4.74, dNLR >3.29, and LLR >166.8 were significantly associated with a worse OS. By multivariate analysis, the MSKCC score and LLR were confirmed as independent prognostic parameters for poorer OS. OS, however, was not significantly different between low- and intermediate-risk groups according to the MSKCC score, while LLR proved to be prognostically relevant and was thus used to develop a novel, effective three-tier PCNSL scoring system. Of 124 patients, 84 patients with survival data and LLR data were successfully validated by newly established PCNSL LLR scoring system. In the present study, we demonstrate that a high LLR represents an independent unfavorable prognostic parameter in PCNSL patients which can be integrated into an effective prognostic model. BackgroundPrimary central nervous system lymphoma (PCNSL) is a highly aggressive and rare extranodal non-Hodgkin lymphoma (NHL). The MSKCC and the IELSG scores represent the most widely used prognostic models, but many changes have occurred in therapeutic protocols since their development. Moreover, many PCNSL patients cannot be classified using the IELSG score. We thus aimed to create a novel, effective and feasible prognostic model for PCNSL.MethodsWe included 248 PCNSL patients diagnosed with PCNSL. Our primary endpoint was the overall survival (OS) and we used the receiver operating characteristic (ROC) analysis to determine the optimal prognostic cut-off value for LLR (lactate dehydrogenase-to-lymphocyte ratio), neutrophil-to-lymphocyte ratio (NLR) and derived neutrophil-to-lymphocyte ratio (dNLR). Variable associated with OS were evaluated by univariate and multivariate analyses. 124 out of 248 patients were randomly selected as the internal validation cohort.ResultsBy univariate analysis, an age >60 years, Eastern Cooperative Oncology Group performance status (ECOG PS) >1, treatment with radiotherapy alone, high-risk groups of Memorial Sloan Kettering Cancer Center (MSKCC) score, NLR >4.74, dNLR >3.29, and LLR >166.8 were significantly associated with a worse OS. By multivariate analysis, the MSKCC score and LLR were confirmed as independent prognostic parameters for poorer OS. OS, however, was not significantly different between low- and intermediate-risk groups according to the MSKCC score, while LLR proved to be prognostically relevant and was thus used to develop a novel, effective three-tier PCNSL scoring system. Of 124 patients, 84 patients with survival data and LLR data were successfully validated by newly established PCNSL LLR scoring system.ConclusionsIn the present study, we demonstrate that a high LLR represents an independent unfavorable prognostic parameter in PCNSL patients which can be integrated into an effective prognostic model. |
Author | Kim, Seok Jin Pellerino, Alessia Zheng, Yanfang Bertero, Luca Tamagnone, Luca He, Yingzhi Cassoni, Paola Lai, Jing Deutsch, Alexander Zhan, Huien Wang, Yao Theresa, Prochazka Katharina Gao, Yuting Wang, Liang Wei, Li You, Hua |
AuthorAffiliation | 12 Department of Hematology, The First Affiliated Hospital of Jinan University , Guangzhou , China 9 Università Cattolica del Sacro Cuore, Department of Life Sciences and Public Health , Rome , Italy 1 Department of Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University , Guangzhou , China 6 Department of Oncology, ZhuJiang Hospital of Southern Medical University , Guangzhou , China 3 Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , South Korea 4 Department of Hematology, Beijing Tongren Hospital, Capital Medical University , Beijing , China 8 Department of Neuro-Oncology, University and City of Health and Science Hospital , Torino , Italy 5 Department of Hematology, ZhuJiang Hospital of Southern Medical University , Guangzhou , China 10 Fondazione Policlinico Universitario “A. Gemelli”- IRCCS , Rome , Italy 7 Pathology Unit, Department of Medical Sciences, University of Turin , Torino |
AuthorAffiliation_xml | – name: 1 Department of Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University , Guangzhou , China – name: 6 Department of Oncology, ZhuJiang Hospital of Southern Medical University , Guangzhou , China – name: 3 Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , South Korea – name: 5 Department of Hematology, ZhuJiang Hospital of Southern Medical University , Guangzhou , China – name: 12 Department of Hematology, The First Affiliated Hospital of Jinan University , Guangzhou , China – name: 8 Department of Neuro-Oncology, University and City of Health and Science Hospital , Torino , Italy – name: 11 Clinical Department of Hematology, Medical University of Graz , Graz , Austria – name: 10 Fondazione Policlinico Universitario “A. Gemelli”- IRCCS , Rome , Italy – name: 7 Pathology Unit, Department of Medical Sciences, University of Turin , Torino , Italy – name: 4 Department of Hematology, Beijing Tongren Hospital, Capital Medical University , Beijing , China – name: 9 Università Cattolica del Sacro Cuore, Department of Life Sciences and Public Health , Rome , Italy – name: 2 NHC Key Laboratory of Birth Defects and Reproductive Health, Chongqing Population and Family Planning Science and Technology Research Institute , Chongqing , China |
Author_xml | – sequence: 1 givenname: Yuting surname: Gao fullname: Gao, Yuting organization: Department of Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China – sequence: 2 givenname: Li surname: Wei fullname: Wei, Li organization: NHC Key Laboratory of Birth Defects and Reproductive Health, Chongqing Population and Family Planning Science and Technology Research Institute, Chongqing, China – sequence: 3 givenname: Seok Jin surname: Kim fullname: Kim, Seok Jin organization: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea – sequence: 4 givenname: Liang surname: Wang fullname: Wang, Liang organization: Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing, China – sequence: 5 givenname: Yingzhi surname: He fullname: He, Yingzhi organization: Department of Hematology, ZhuJiang Hospital of Southern Medical University, Guangzhou, China – sequence: 6 givenname: Yanfang surname: Zheng fullname: Zheng, Yanfang organization: Department of Oncology, ZhuJiang Hospital of Southern Medical University, Guangzhou, China – sequence: 7 givenname: Luca surname: Bertero fullname: Bertero, Luca organization: Pathology Unit, Department of Medical Sciences, University of Turin, Torino, Italy – sequence: 8 givenname: Alessia surname: Pellerino fullname: Pellerino, Alessia organization: Department of Neuro-Oncology, University and City of Health and Science Hospital, Torino, Italy – sequence: 9 givenname: Paola surname: Cassoni fullname: Cassoni, Paola organization: Pathology Unit, Department of Medical Sciences, University of Turin, Torino, Italy – sequence: 10 givenname: Luca surname: Tamagnone fullname: Tamagnone, Luca organization: Fondazione Policlinico Universitario "A. Gemelli"- IRCCS, Rome, Italy – sequence: 11 givenname: Prochazka Katharina surname: Theresa fullname: Theresa, Prochazka Katharina organization: Clinical Department of Hematology, Medical University of Graz, Graz, Austria – sequence: 12 givenname: Alexander surname: Deutsch fullname: Deutsch, Alexander organization: Clinical Department of Hematology, Medical University of Graz, Graz, Austria – sequence: 13 givenname: Huien surname: Zhan fullname: Zhan, Huien organization: Department of Hematology, The First Affiliated Hospital of Jinan University, Guangzhou, China – sequence: 14 givenname: Jing surname: Lai fullname: Lai, Jing organization: Department of Hematology, The First Affiliated Hospital of Jinan University, Guangzhou, China – sequence: 15 givenname: Yao surname: Wang fullname: Wang, Yao organization: Department of Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China – sequence: 16 givenname: Hua surname: You fullname: You, Hua organization: Department of Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34422649$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkk1vEzEQhleoiJbSOyfkI5cN_lrvmgNSlUKJSEvVgOBmOd5xsu2uHWynKL-LP4jDlqr1xdY7M894Ru_L4sB5B0XxmuAJY418Z70zE4opmQgpCK-fFUeUMl5Kzn4ePHofFicx3uB8RIUJZi-KQ8Y5pYLLo-LPKbr0d9Cjq-BXzsfUGXShwy0EZH3IajfosEPTywWa74bN2g_6PZprk3QCdAbrXZvrwOkIZfLlmGJ2OXatU-fRbNiEjI9okUIWbGf2skPeoqv8Apci-tGldedQWgOa-99IuxbNXIIwQNvtu1wsvkyn6LqLt-g8-O0mviqeW91HOLm_j4vvnz5-m34u51_PZ9PTeWm4oKlcEtYAtEtMWsZpxSqDma6tlFbwSi5NzVoJeSPQClszaQjlGoCZBhrGgNfsuJiN3NbrG7UZV6G87tQ_wYeV0iEvrAdVYQxMCCOYbHllRdNYQZaGWyakwabNrA8ja7Nd5sFMnjzo_gn0acR1a7Xyd6phNW6qKgPe3gOC_7WFmNTQRQN9rx34bVS0EqwmFaEkp-Ix1QQfYwD70IZgtbeO2ltH7a2jRuvkkjePv_dQ8N8o7C9AicUt |
CitedBy_id | crossref_primary_10_1007_s11060_023_04337_z crossref_primary_10_1007_s10143_023_02248_1 crossref_primary_10_1007_s11060_024_04692_5 crossref_primary_10_1093_noajnl_vdad136 crossref_primary_10_1186_s43556_023_00141_3 crossref_primary_10_3389_fonc_2023_1104425 crossref_primary_10_1111_ejh_14159 crossref_primary_10_2298_MPNS22S1073V |
Cites_doi | 10.1038/bjc.2014.277 10.1016/S0360-3016(97)00571-3 10.1371/journal.pone.0134732 10.1159/000491988 10.1038/bjc.2013.763 10.1038/nature22079 10.1016/S0360-3016(98)00564-1 10.1016/j.ijrobp.2003.11.001 10.1038/oncsis.2014.16 10.1002/brb3.928 10.1016/S1470-2045(14)70263-3 10.18632/oncotarget.20480 10.1200/JCO.2003.03.108 10.1016/j.ejca.2016.01.016 10.1007/s12253-019-00707-z 10.1200/JCO.2003.09.139 10.1007/s11899-014-0217-2 10.1200/JCO.1999.17.4.1244 10.5301/tj.5000694 10.1080/14737140.2019.1677157 10.1159/000487288 10.1200/JCO.2006.08.2941 10.1002/cam4.2872 10.1016/j.ygyno.2006.05.043 10.1200/JCO.2002.11.013 10.1200/JCO.2003.11.036 10.3389/fimmu.2016.00052 10.18632/oncotarget.16720 10.1200/JCO.1998.16.3.859 10.18632/oncotarget.25306 10.1007/s00277-014-2115-z 10.1186/s12885-016-2397-8 10.1038/nature01322 |
ContentType | Journal Article |
Copyright | Copyright © 2021 Gao, Wei, Kim, Wang, He, Zheng, Bertero, Pellerino, Cassoni, Tamagnone, Theresa, Deutsch, Zhan, Lai, Wang and You. Copyright © 2021 Gao, Wei, Kim, Wang, He, Zheng, Bertero, Pellerino, Cassoni, Tamagnone, Theresa, Deutsch, Zhan, Lai, Wang and You 2021 Gao, Wei, Kim, Wang, He, Zheng, Bertero, Pellerino, Cassoni, Tamagnone, Theresa, Deutsch, Zhan, Lai, Wang and You |
Copyright_xml | – notice: Copyright © 2021 Gao, Wei, Kim, Wang, He, Zheng, Bertero, Pellerino, Cassoni, Tamagnone, Theresa, Deutsch, Zhan, Lai, Wang and You. – notice: Copyright © 2021 Gao, Wei, Kim, Wang, He, Zheng, Bertero, Pellerino, Cassoni, Tamagnone, Theresa, Deutsch, Zhan, Lai, Wang and You 2021 Gao, Wei, Kim, Wang, He, Zheng, Bertero, Pellerino, Cassoni, Tamagnone, Theresa, Deutsch, Zhan, Lai, Wang and You |
DBID | NPM AAYXX CITATION 7X8 5PM DOA |
DOI | 10.3389/fonc.2021.696147 |
DatabaseName | PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed |
Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: http://www.doaj.org/ sourceTypes: Open Website |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2234-943X |
EndPage | 696147 |
ExternalDocumentID | oai_doaj_org_article_500e366c639d45f688f61bc4f369c0cd 10_3389_fonc_2021_696147 34422649 |
Genre | Journal Article |
GrantInformation_xml | – fundername: National Natural Science Foundation of China grantid: 81911530169, 81903088, 81670180 |
GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD ACGFO ACGFS ACXDI ADBBV ADRAZ AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV DIK EBS EJD EMOBN GROUPED_DOAJ GX1 HYE IAO IEA IHR IHW IPNFZ KQ8 M48 M~E NPM OK1 PGMZT RIG RNS RPM AAYXX CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c462t-b138eedb01d342535c03a7f99f6459bc73d9e501ed6f739c124aee3c8e833e473 |
IEDL.DBID | RPM |
ISSN | 2234-943X |
IngestDate | Tue Oct 22 15:11:50 EDT 2024 Tue Sep 17 21:28:36 EDT 2024 Fri Oct 25 01:52:00 EDT 2024 Thu Nov 21 21:22:28 EST 2024 Sat Sep 28 08:23:54 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | Memorial Sloan Kettering Cancer Center (MSKCC) score neutrophil-to-lymphocyte ratio lactate dehydrogenase-to-lymphocyte ratio prognostic parameter primary central nervous system lymphoma |
Language | English |
License | Copyright © 2021 Gao, Wei, Kim, Wang, He, Zheng, Bertero, Pellerino, Cassoni, Tamagnone, Theresa, Deutsch, Zhan, Lai, Wang and You. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c462t-b138eedb01d342535c03a7f99f6459bc73d9e501ed6f739c124aee3c8e833e473 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Reviewed by: Chan-Sik Park, University of Ulsan, South Korea; Albrecht Reichle, University Medical Center Regensburg, Germany Edited by: Liren Qian, Fifth Medical Center of the PLA General Hospital, China These authors have contributed equally to this work This article was submitted to Hematologic Malignancies, a section of the journal Frontiers in Oncology |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370855/ |
PMID | 34422649 |
PQID | 2563715121 |
PQPubID | 23479 |
PageCount | 1 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_500e366c639d45f688f61bc4f369c0cd pubmedcentral_primary_oai_pubmedcentral_nih_gov_8370855 proquest_miscellaneous_2563715121 crossref_primary_10_3389_fonc_2021_696147 pubmed_primary_34422649 |
PublicationCentury | 2000 |
PublicationDate | 2021-08-03 |
PublicationDateYYYYMMDD | 2021-08-03 |
PublicationDate_xml | – month: 08 year: 2021 text: 2021-08-03 day: 03 |
PublicationDecade | 2020 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland |
PublicationTitle | Frontiers in oncology |
PublicationTitleAlternate | Front Oncol |
PublicationYear | 2021 |
Publisher | Frontiers Media S.A |
Publisher_xml | – name: Frontiers Media S.A |
References | Romero-Garcia (B20) 2016; 7 Jahr (B31) 2018; 8 Keane (B18) 2018; 9 Dai (B16) 2017; 8 Go (B12) 2018; 104 Cheson (B19) 1999; 17 Bessell (B32) 2004; 59 Poortmans (B5) 2003; 21 Abrey (B4) 1998; 16 Jung (B28) 2017; 8 Huang (B15) 2017; 545 Hoang-Xuan (B30) 2003; 21 DeAngelis (B3) 2002; 20 Kim (B8) 2016; 16 Ji (B14) 2018; 45 Corry (B26) 1998; 41 Diakos (B25) 2014; 15 Hayabuchi (B27) 1999; 44 Troppan (B9) 2014; 111 Jang (B11) 2016; 57 Seidel (B2) 2019; 19 Phillips (B1) 2014; 9 Coussens (B10) 2002; 420 Abrey (B7) 2006; 24 Liu (B33) 2020; 9 Ferreri (B6) 2003; 21 Li (B17) 2020; 26 Passardi (B21) 2015; 10 Troppan (B13) 2014; 110 Park (B24) 2014; 93 Giatromanolaki (B22) 2006; 103 Allison (B23) 2014; 3 Uz (B29) 2018; 140 |
References_xml | – volume: 111 start-page: 55 year: 2014 ident: B9 article-title: C-Reactive Protein Level Is a Prognostic Indicator for Survival and Improves the Predictive Ability of the R-IPI Score in Diffuse Large B-Cell Lymphoma Patients publication-title: Br J Cancer doi: 10.1038/bjc.2014.277 contributor: fullname: Troppan – volume: 41 year: 1998 ident: B26 article-title: Primary Central Nervous System Lymphoma: Age and Performance Status Are More Important Than Treatment Modality publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/S0360-3016(97)00571-3 contributor: fullname: Corry – volume: 10 start-page: e0134732 year: 2015 ident: B21 article-title: Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients With Metastatic Colorectal Cancer publication-title: PloS One doi: 10.1371/journal.pone.0134732 contributor: fullname: Passardi – volume: 140 year: 2018 ident: B29 article-title: The Prognostic Value of the Derived Neutrophil-to-Lymphocyte Ratio in Transplantation-Ineligible Patients With Multiple Myeloma publication-title: Acta Haematol doi: 10.1159/000491988 contributor: fullname: Uz – volume: 110 year: 2014 ident: B13 article-title: The Derived Neutrophil to Lymphocyte Ratio Is an Independent Prognostic Factor in Patients With Diffuse Large B-Cell Lymphoma publication-title: Br J Cancer doi: 10.1038/bjc.2013.763 contributor: fullname: Troppan – volume: 545 year: 2017 ident: B15 article-title: T-Cell Invigoration to Tumour Burden Ratio Associated With Anti-PD-1 Response publication-title: Nature doi: 10.1038/nature22079 contributor: fullname: Huang – volume: 44 year: 1999 ident: B27 article-title: Primary Central Nervous System Lymphoma in Japan: A Nationwide Survey publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/S0360-3016(98)00564-1 contributor: fullname: Hayabuchi – volume: 59 year: 2004 ident: B32 article-title: Primary Non-Hodgkin’s Lymphoma of the CNS Treated With CHOD/BVAM or BVAM Chemotherapy Before Radiotherapy: Long-Term Survival and Prognostic Factors publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2003.11.001 contributor: fullname: Bessell – volume: 3 start-page: e102 year: 2014 ident: B23 article-title: Identification of LDH-A as a Therapeutic Target for Cancer Cell Killing Via (I) p53/NAD(H)-Dependent and (Ii) p53-independent Pathways publication-title: Oncogenesis doi: 10.1038/oncsis.2014.16 contributor: fullname: Allison – volume: 8 start-page: e00928 year: 2018 ident: B31 article-title: Evaluation of Memorial Sloan-Kettering Cancer Center and International Extranodal Lymphoma Study Group Prognostic Scoring Systems to Predict Overall Survival in Intracranial Primary CNS Lymphoma publication-title: Brain Behav doi: 10.1002/brb3.928 contributor: fullname: Jahr – volume: 15 year: 2014 ident: B25 article-title: Cancer-Related Inflammation and Treatment Effectiveness publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)70263-3 contributor: fullname: Diakos – volume: 8 year: 2017 ident: B28 article-title: Prognostic Role of the Neutrophil-to-Lymphocyte Ratio in Patients With Primary Central Nervous System Lymphoma publication-title: Oncotarget doi: 10.18632/oncotarget.20480 contributor: fullname: Jung – volume: 21 year: 2003 ident: B5 article-title: High-Dose Methotrexate-Based Chemotherapy Followed by Consolidating Radiotherapy in Non-AIDS-Related Primary Central Nervous System Lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962 publication-title: J Clin Oncol: Off J Am Soc Clin Oncol doi: 10.1200/JCO.2003.03.108 contributor: fullname: Poortmans – volume: 57 year: 2016 ident: B11 article-title: A New Prognostic Model Using Absolute Lymphocyte Count in Patients With Primary Central Nervous System Lymphoma publication-title: Eur J Cancer (Oxford England: 1990) doi: 10.1016/j.ejca.2016.01.016 contributor: fullname: Jang – volume: 26 year: 2020 ident: B17 article-title: Lactate Dehydrogenase-to-Lymphocyte Ratio Represents a Powerful Prognostic Tool of Metastatic Renal Cell Carcinoma Patients Treated With Tyrosine Kinase Inhibitors publication-title: Pathol Oncol Research: POR doi: 10.1007/s12253-019-00707-z contributor: fullname: Li – volume: 21 year: 2003 ident: B6 article-title: Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group Experience publication-title: J Clin Oncol: Off J Am Soc Clin Oncol doi: 10.1200/JCO.2003.09.139 contributor: fullname: Ferreri – volume: 9 year: 2014 ident: B1 article-title: Primary CNS Lymphoma publication-title: Curr Hematol Malignancy Rep doi: 10.1007/s11899-014-0217-2 contributor: fullname: Phillips – volume: 17 start-page: 1244 year: 1999 ident: B19 article-title: Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin’s Lymphomas. NCI Sponsored International Working Group publication-title: J Clin Oncol: Off J Am Soc Clin Oncol doi: 10.1200/JCO.1999.17.4.1244 contributor: fullname: Cheson – volume: 104 year: 2018 ident: B12 article-title: A New Prognostic Model Using the NCCN-IPI and Neutrophil-to-Lymphocyte Ratio in Diffuse Large B-Cell Lymphoma publication-title: Tumori doi: 10.5301/tj.5000694 contributor: fullname: Go – volume: 19 year: 2019 ident: B2 article-title: Have Treatment Protocols for Primary CNS Lymphoma Advanced in the Past 10 Years publication-title: Expert Rev Anticancer Ther doi: 10.1080/14737140.2019.1677157 contributor: fullname: Seidel – volume: 45 year: 2018 ident: B14 article-title: Ratio of Immune Response to Tumor Burden Predicts Survival Via Regulating Functions of Lymphocytes and Monocytes in Diffuse Large B-Cell Lymphoma publication-title: Cell Physiol Biochem: Int J Exp Cell Physiol Biochem Pharmacol doi: 10.1159/000487288 contributor: fullname: Ji – volume: 24 year: 2006 ident: B7 article-title: Primary Central Nervous System Lymphoma: The Memorial Sloan-Kettering Cancer Center Prognostic Model publication-title: J Clin Oncol: Off J Am Soc Clin Oncol doi: 10.1200/JCO.2006.08.2941 contributor: fullname: Abrey – volume: 9 year: 2020 ident: B33 article-title: A New Prognostic Score for Disease Progression and Mortality in Patients With Newly Diagnosed Primary CNS Lymphoma publication-title: Cancer Med doi: 10.1002/cam4.2872 contributor: fullname: Liu – volume: 103 year: 2006 ident: B22 article-title: Lactate Dehydrogenase 5 (LDH-5) Expression in Endometrial Cancer Relates to the Activated VEGF/VEGFR2(KDR) Pathway and Prognosis publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2006.05.043 contributor: fullname: Giatromanolaki – volume: 20 year: 2002 ident: B3 article-title: Combination Chemotherapy and Radiotherapy for Primary Central Nervous System Lymphoma: Radiation Therapy Oncology Group Study 93-10 publication-title: J Clin Oncol: Off J Am Soc Clin Oncol doi: 10.1200/JCO.2002.11.013 contributor: fullname: DeAngelis – volume: 21 year: 2003 ident: B30 article-title: Chemotherapy Alone as Initial Treatment for Primary CNS Lymphoma in Patients Older Than 60 Years: A Multicenter Phase II Study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group publication-title: J Clin Oncol: Off J Am Soc Clin Oncol doi: 10.1200/JCO.2003.11.036 contributor: fullname: Hoang-Xuan – volume: 7 year: 2016 ident: B20 article-title: Lactate Contribution to the Tumor Microenvironment: Mechanisms, Effects on Immune Cells and Therapeutic Relevance publication-title: Front Immunol doi: 10.3389/fimmu.2016.00052 contributor: fullname: Romero-Garcia – volume: 8 year: 2017 ident: B16 article-title: Development of New Prognostic Model Based on Pretreatment βlri and LLRI for Stage IE/IIE Upper Aerodigestive Tract ENKTL, Nasal Type publication-title: Oncotarget doi: 10.18632/oncotarget.16720 contributor: fullname: Dai – volume: 16 year: 1998 ident: B4 article-title: Long-Term Survival in Primary CNS Lymphoma publication-title: J Clin Oncol: Off J Am Soc Clin Oncol doi: 10.1200/JCO.1998.16.3.859 contributor: fullname: Abrey – volume: 9 year: 2018 ident: B18 article-title: A High LDH to Absolute Lymphocyte Count Ratio in Patients With DLBCL Predicts for a Poor Intratumoral Immune Response and Inferior Survival publication-title: Oncotarget doi: 10.18632/oncotarget.25306 contributor: fullname: Keane – volume: 93 year: 2014 ident: B24 article-title: The Highest Prognostic Impact of LDH Among International Prognostic Indices (Ipis): An Explorative Study of Five IPI Factors Among Patients With DLBCL in the Era of Rituximab publication-title: Ann Hematol doi: 10.1007/s00277-014-2115-z contributor: fullname: Park – volume: 16 start-page: 363 year: 2016 ident: B8 article-title: MYC and BCL2 Overexpression Is Associated With a Higher Class of Memorial Sloan-Kettering Cancer Center Prognostic Model and Poor Clinical Outcome in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System publication-title: BMC Cancer doi: 10.1186/s12885-016-2397-8 contributor: fullname: Kim – volume: 420 year: 2002 ident: B10 article-title: Inflammation and Cancer publication-title: Nature doi: 10.1038/nature01322 contributor: fullname: Coussens |
SSID | ssj0000650103 |
Score | 2.3667855 |
Snippet | Primary central nervous system lymphoma (PCNSL) is a highly aggressive and rare extranodal non-Hodgkin lymphoma (NHL). The MSKCC and the IELSG scores represent... BACKGROUNDPrimary central nervous system lymphoma (PCNSL) is a highly aggressive and rare extranodal non-Hodgkin lymphoma (NHL). The MSKCC and the IELSG scores... BackgroundPrimary central nervous system lymphoma (PCNSL) is a highly aggressive and rare extranodal non-Hodgkin lymphoma (NHL). The MSKCC and the IELSG scores... |
SourceID | doaj pubmedcentral proquest crossref pubmed |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 696147 |
SubjectTerms | lactate dehydrogenase-to-lymphocyte ratio Memorial Sloan Kettering Cancer Center (MSKCC) score neutrophil-to-lymphocyte ratio Oncology primary central nervous system lymphoma prognostic parameter |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagB8QF8Sa8NEhcOITGcRLH3Mq2VSW2q6oLglvk-KFdFRK02W21v4s_yIy9XXUREheusZNY_saez_b4G8beWqQEPitcis5MpIXKTdrqzKdce8EtEv4i5AY8mcrJt_rwiGRytqm-KCYsygPHjtsvs8yJqjLoSW1R-qqufcVbU3hRKZMZG2bfrLqxmIpzcEkJDOK5JK7C1L7vO1IszPn7SqFLkjt-KMj1_41j_hkqecP3HN9n9zakEQ5iYx-wW657yO6cbo7FH7FfBzDpL913OFv0FDiH1YAu4bgFICfFp0FRAkaTKYzXCF__Q3-AsTZENOHQzdYW33MdOrR02aexillj2TnhBnHjwQ0QpGwptijACb2HsyjLOsDX-XI27wDpJIz7K9CdhbDZGG6m4JdOp59GIzifDxcQtruGx-zL8dHn0Um6ycaQmqLKl2nLRY0Otc24FTjQRWkyoaVXypMeTWuksMphrztbeSmUQeKgnROmdrUQrpDiCdvr-s49Y-BxUihbwy3Sm6K0CKf0XOksb3OvZZsn7N01Ns3P2EUNLlYIx4ZwbAjHJuKYsI8E3rYeyWWHB2hEzcaImn8ZUcLeXEPf4PCiMxPduX41NMgIhSRWxBP2NJrC9leiCNeQVcLkjpHstGW3pJvPgoQ3SQ7VZfn8fzT-BbtL_RGiEsVLtrdcrNwrdnuwq9dhUPwGsI4UHQ priority: 102 providerName: Directory of Open Access Journals |
Title | A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups |
URI | https://www.ncbi.nlm.nih.gov/pubmed/34422649 https://search.proquest.com/docview/2563715121 https://pubmed.ncbi.nlm.nih.gov/PMC8370855 https://doaj.org/article/500e366c639d45f688f61bc4f369c0cd |
Volume | 11 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LjtMwFLXoLBAbxJvwGF0kNizSJnFeZjdkZjQSbVVNQbCLHD-mEdN41LSgfhc_yLWTjKaIFVs_4sjn2vfYvj4m5L1ESqCDWPnozKgfs0j4FQ-0H3JNQ4mEP3ZvA14ss_n3_PTMyuQkw10YF7QvqnrcXK_HTb1ysZU3azEZ4sQmi1lhBVvyJJmMyAi54Z0lejf9Jvbtgu5IEhdgbKJNY8UKo3CcMvRG9t09GrsbpOzAGznR_n8xzb8DJu94oPNH5GFPHeGk-8XH5J5qnpD7s_5w_Cn5fQJz81Ndw2JjbPgcFgN7FUdtAJkppjpdCSjmS5juEUSz5h9hyoWlm3CqVnuJ9VSDbs3fGr8rIvaYd2nRg277QbXgBG1thJEDFYyGRSfO2sK3eruqG0BSCVPzC3gjwW05uvsp-KXZ8nNRwGXd_gC36dU-I1_Pz74UF37_JoMv4jTa-lVIc3SrVRBKisOdJiKgPNOMaatKU4mMSqYQACVTnVEmkD5wpajIVU6pijP6nBw1plEvCWicGpJKhBJJTpzIECvrkPEgqiLNsyryyIcBm_Km66ISlywW0tJCWlpIyw5Sj3yy4N2Ws6LZLsFsrsredMokCBRNU4GkTMaJTvNcp9hqrGnKRCCkR94N0Jc4yOzJCW-U2bUl8kKaWW4UeuRFZwq3TQ2m5JHswEgO_uUwB-3aCXn3dvzqv2u-Jg9sJ7iARPqGHG03O_WWjFq5O3abC8duaPwBbc0Vxg |
link.rule.ids | 230,315,729,782,786,866,887,2106,27933,27934,53800,53802 |
linkProvider | National Library of Medicine |
linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbYkIAX7rBwPUi88JA2iXMzbyPbVLS0qtYheIsSX2i11ZmaFtTfxR_k2EmmFfG0V1_iyOezz2f7-DMhHwVSAuWF0kVnRt2QBdytSk-5fqmoL5Dwh_ZtwNEsmfxIj46NTE7U34WxQfu8Wgz05XKgF3MbW3m15MM-Tmw4HWdGsCWNouEeuYvj1fNuLNLbCTgyrxe0h5K4BGNDVWsjVxj4g5ihPzIv79HQ3iFlO_7Iyvb_j2v-GzJ5wwedPLrl3z8mDzvSCYdt9hNyR-qn5N64O1Z_Rv4cwqT-JS9huqpN4B0WA3OJR64AOS2mWkUKyCYzyLdo_npZfoa85IaowpGcbwXWkxodoruu3bYI32LembE7tBsXsgErhWtikywcoFYwbWVdG_i-WM8XGpCOQl7_hlILsJuV9mYLfmk8O80yOFs0F2C3y5rn5NvJ8Xk2crvXHFwexsHarXyaokOuPF9QnChoxD1aJooxZfRsKp5QwSQaTopYJZRxJB6llJSnMqVUhgl9QfZ1reUBAYWTSlRxXyA9CiPhY2Xls9ILqkCVSRU45FNv0-Kq7aICFzsGCoWBQmGgULRQcMgXY_TrckZu2ybUq59FZ7Yi8jxJ45gjnRNhpOI0VTG2GioaM-5x4ZAPPWQKHJ7mzKXUst40BTJKmhhW5TvkZQuh66Z6CDok2QHXzr_s5iCmrAR4h6FXt675ntwfnY_zIv86OX1NHpgOsWGN9A3ZX6828i3Za8TmnR1YfwFbFipd |
linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwELbYRVpx4c0SnoPEhUPaJM7L3JZ0q0XbVtUWBLco8YNGbJ2qaUH9XfxBxk5abREnuCZ2Hp7Pns_2-BtC3gqkBMoLpYvOjLohC7hbFp5y_UJRXyDhD21uwItZMvmaDs6NTM4-1ZcN2udl1dPXi56u5ja2crng_V2cWH86zoxgSxpF_aVQ_SNyG_usF9yYqLeDcGQyGLQbkzgNY31VayNZGPi9mKFPMtn3aGjPkbIDn2Sl-__GN_8Mm7zhh4b3_uMP7pO7HfmEs7bIA3JL6ofkZNxtrz8iv85gUv-Q1zBd1SYAD4uBOcwjV4DcFq9aZQrIJjMYbREG9aJ4D6OCG8IKAznfCqwnNTpGd127bRG-xXtXxv7QLmDIBqwkrolRsrCAWsG0lXdt4Eu1nlcakJbCqP4JhRZgFy3tCRd80nh2mWVwVTXfwS6bNY_J5-H5p-zC7bI6uDyMg7Vb-jRFx1x6vqA4YNCIe7RIFGPK6NqUPKGCSTSeFLFKKONIQAopKU9lSqkME_qEHOtay6cEFA4uUcl9gTQpjISPlZXPCi8oA1UkZeCQdzu75su2iXKc9Bg45AYOuYFD3sLBIR-M4ffljOy2vVCvvuWd6fLI8ySNY460ToSRitNUxfjWUNGYcY8Lh7zZwSbHbmr2Xgot602TI7OkiWFXvkNOWxjtX7WDoUOSA4AdfMvhHcSVlQLvcPTsn2u-JifTwTAffZxcPid3THvY6Eb6ghyvVxv5khw1YvPK9q3fl0Ys3Q |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+Novel+Prognostic+Marker+for+Primary+CNS+Lymphoma%3A+Lactate+Dehydrogenase-to-Lymphocyte+Ratio+Improves+Stratification+of+Patients+Within+the+Low+and+Intermediate+MSKCC+Risk+Groups&rft.jtitle=Frontiers+in+oncology&rft.au=Gao%2C+Yuting&rft.au=Wei%2C+Li&rft.au=Kim%2C+Seok+Jin&rft.au=Wang%2C+Liang&rft.date=2021-08-03&rft.issn=2234-943X&rft.eissn=2234-943X&rft.volume=11&rft.spage=696147&rft.epage=696147&rft_id=info:doi/10.3389%2Ffonc.2021.696147&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2234-943X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2234-943X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2234-943X&client=summon |